Table 1

Baseline characteristics of initial 80 patients receiving inclisiran

FH n=30Non-FH n=50Total n=80
Sex n (%)
 Male18 (60)34 (68)52 (65)
 Female12 (40)16 (32)28 (35)
Age, mean (SD, range)61.7 (±12.6, 34–83)65.3 (±8.5, 51–83)64 (±10.3, 34–83)
Ethnicity n (%)
 Asian8 (26.7)10 (20)18 (22.5)
 Black2 (6.7)2 (2.5)
 Mixed1 (3.3)2 (4)3 (3.8)
 Other3 (10)9 (18)12 (15)
 White16 (53.3)29 (58)45 (56.3)
Atherosclerotic disease n (%)
 Coronary artery disease23 (76.7)44 (88)67 (83.8)
 CABG2 (6.7)7 (34)9 (11.3)
 MI8 (26.7)12 (24)20 (25)
 PCI2 (6.7)13 (26)15 (18.8)
 Subclinical cor. disease11 (36.7)17 (34)28 (35)
 Cerebrovascular disease4 (13.3)10 (20)14 (17.5)
 Stroke1 (3.3)1 (2)2 (2.5)
 TIA1 (3.3)3 (6)4 (5)
 Subclinical carotid disease2 (6.7)6 (12)8 (10)
 Peripheral arterial disease1 (3.3)3 (6)4 (5)
Cardiovascular risk factors n (%)
 Hypertension7 (23.3)25 (50)32 (40)
 Diabetes mellitus3 (10)16 (32)19 (23.8)
 Smoking history3 (10)9 (18)12 (15)
Lipid profile, mmol/L, mean (SD)
 Total cholesterol5.5 (± 1.3)5.9 (± 1.4)5.8 (± 1.4)
 LDL-c3.5 (± 1.2)3.6 (±1.1)3.5 (± 1.2)
 Triglycerides*1.4 (1.0–1.4)1.7 (1.3–2.9)1.6 (1.2–2.3)
 HDL-c1.4 (±0.3)1.3 (±0.4)1.3 (±0.4)
Lipid-lowering treatment † n (%)
 Atorvastatin alone5 (16.7)4 (8)9 (11.3)
 Medium intensity
 High intensity549
 Rosuvastatin alone1 (3.3)1 (2)2 (2.5)
 Medium intensity11
 High intensity11
 Ezetimibe alone3 (10)10 (20)13 (16.3)
 Statin and ezetimibe14 (46.7)6 (12)20 (25)
 Medium intensity statin11
 High intensity statin14519
 Colesevelam alone1 (3.3)1 (2)2 (2.5)
 Bempedoic acid1 (2)1 (1.3)
 Bempedoic acid and ezetimibe1 (2)1 (1.3)
 Triple combinative therapy‡6 (20)7 (14)13 (16.3)
 Medium intensity statin11
 High intensity statin6410
 No lipid-lowering treatment19 (38)19 (23.8)
  • *Triglyceride values reported as median (IQR).

  • †Denotes medications patients were taking at baseline, statins were further divided into medium and high intensity doses.

  • ‡Defined as those taking three drugs from a combination of statins, ezetimibe, colesevelam and fibrates.

  • CABG, coronary artery bypass graft; FH, familial hypercholesterolaemia; HDL-c, high-density lipoprotein cholesterol; LDL-c, Low-density lipoprotein cholesterol; MI, myocardial infarction; Non-FH, Non familial hypercholesterolaemia; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.